[Anti-hepatitis C Virus Strategy Targeting the Entry Steps]

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Hepatitis C virus (HCV) infection causes severe liver disease, including cirrhosis and hepatocellular carcinoma.
• Direct-acting antivirals (DAAs) are effective but face challenges due to HCV's high mutation rate and potential drug resistance.
• Emerging DAA-resistant variants necessitate the development of novel anti-HCV therapeutics targeting different mechanisms.

Purpose of the Study:

• To explore host factors involved in HCV cellular entry.
• To identify and evaluate novel host-targeting anti-HCV entry inhibitors.
• To present strategies for developing new anti-HCV therapies, particularly those targeting viral entry steps.

Main Methods:

• Investigating host cellular factors crucial for HCV entry.
• Developing monoclonal antibodies targeting specific HCV receptors.
• Evaluating the efficacy of host-targeting inhibitors in combination with DAAs.

Main Results:

• Identification of novel host factors implicated in HCV cell entry.
• Development of promising monoclonal antibody candidates against HCV entry receptors.
• Demonstration of potential synergistic effects when combining entry inhibitors with DAAs.

Conclusions:

• Host-targeting strategies, especially those focused on HCV entry, represent a viable approach to overcome DAA resistance.
• Monoclonal antibodies against HCV receptors offer a potential adjunct therapy to DAAs.
• Continued research into host-viral interactions is critical for developing next-generation anti-HCV treatments.